Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Increase in Short Interest

Zealand Pharma A/S (OTCMKTS:ZLDPF) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 1,588,400 shares, an increase of 28.4% from the January 15th total of 1,237,500 shares. Based on an average daily trading volume, of 2,000 shares, the days-to-cover ratio is currently 794.2 days.

Analyst Upgrades and Downgrades

Several research firms recently commented on ZLDPF. JPMorgan Chase & Co. began coverage on Zealand Pharma A/S in a research report on Friday, November 8th. They set an “overweight” rating for the company. Cantor Fitzgerald upgraded Zealand Pharma A/S to a “strong-buy” rating in a research report on Tuesday, January 21st.

Zealand Pharma A/S Price Performance

ZLDPF opened at $104.01 on Friday. The stock has a 50-day moving average price of $102.19 and a 200-day moving average price of $114.52. Zealand Pharma A/S has a 12-month low of $67.58 and a 12-month high of $141.74. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $7.39 billion, a P/E ratio of -42.80 and a beta of 0.88.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.